

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

COMPUTERIZED THERMAL IMAGING INC
Form 10-Q
November 13, 2001

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2001

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 000-23955

COMPUTERIZED THERMAL IMAGING, INC.

(Exact name of Registrant as specified in its charter)

NEVADA

(State or other jurisdiction of incorporation or
organization)

87-0458721

(IRS Employer
Identification No.)

Two Centerpointe Drive, Suite 450 Lake Oswego, Oregon

(Address of principal executive offices)

97035

(Zip Code)

(503) 594-1210

(Registrant's telephone number, including area code)

Check whether the registrant (1) filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports) and
(2) has been subject to such filing requirements for the past 90 days.

Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS: State the number of shares
outstanding of each of the issuer's classes of common equity, as of the latest
practicable date: Common stock, par value \$0.001, of which 82,803,263 shares
were issued and outstanding as of November 07, 2001.

COMPUTERIZED THERMAL IMAGING, INC.

FORM 10-Q

QUARTERLY REPORT

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

ITEM 1. Financial Statements.....4

 Condensed Consolidated Balance Sheets as of September 30, 2001
 and June 30, 20014

 Condensed Consolidated Statements of Operations for the three
 months ended September 30, 2001 and 2000 and for the period
 from inception on June 10, 1987 to September 30, 20015

 Condensed Consolidated Statement of Stockholder's Equity for
 the three months ended September 30, 2001.....6

 Condensed Consolidated Statements of Cash Flows for the three
 months ended September 30, 2001 and 2000 and for the period from
 inception on June 10, 1987 to September 30, 20017

 Notes to Condensed Consolidated Financial Statements.....9

ITEM 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations.....12

ITEM 3. Quantitative and Qualitative Disclosure of Market Risk.....17

PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings.....18

ITEM 2. Changes in Securities.....20

ITEM 3. Defaults upon Senior Securities.....20

ITEM 4. Submission of Matters to a Vote of Security Holders.....20

ITEM 5. Other Information.....20

ITEM 6. Exhibits and Reports on Form 8-K.....21

SIGNATURES

PART I - FINANCIAL INFORMATION

ITEM 1.

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

(A Development Stage Company)
 CONDENSED CONSOLIDATED BALANCE SHEETS
 (UNAUDITED)

| | September 30, 2001 | June 30, 2001 |
|---|-----------------------|------------------|
| ASSETS | | |
| CURRENT ASSETS: | | |
| Cash and cash equivalents | \$ 6,382,537 | \$ 7,810,000 |
| Investments available for sale | 11,152,192 | 11,070,000 |
| Accounts receivable-trade, net | 562,271 | 383,000 |
| Accounts receivable-other, net | 174,377 | 559,000 |
| Inventories | 946,335 | 643,000 |
| Prepaid expenses | 281,603 | 269,000 |
| Total current assets | 19,499,315 | 20,735,000 |
| PROPERTY AND EQUIPMENT, Net | 1,225,619 | 1,228,000 |
| INTANGIBLE ASSETS: | | |
| Goodwill, net | 9,553,113 | 9,834,000 |
| Intellectual property rights, net | 42,744 | 44,000 |
| Total intangible assets | 9,595,857 | 9,878,000 |
| TOTAL ASSETS | \$ 30,320,791 | \$ 31,843,000 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| CURRENT LIABILITIES: | | |
| Accounts payable | \$ 1,227,956 | \$ 1,802,000 |
| Accrued liabilities | 802,137 | 844,000 |
| Deferred revenues | 365,460 | 11,000 |
| Total current liabilities | 2,395,553 | 2,658,000 |
| COMMITMENTS AND CONTINGENCIES | - | - |
| STOCKHOLDERS' EQUITY: | | |
| Convertible preferred stock, \$5.00 par value, 3,000,000 shares authorized; issued-none | - | - |
| Common stock, \$.001 par value, 200,000,000 shares authorized, 82,803,263 and 81,076,546 issued and outstanding on September 30, 2001 and June 30, 2001, respectively | 82,804 | 81,000 |
| Additional paid-in capital | 88,187,802 | 89,910,000 |
| Other comprehensive income | 86,107 | 106,000 |
| Deficit accumulated during the development stage | (60,431,475) | (60,913,000) |
| Total stockholders' equity | 27,925,238 | 29,184,000 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | \$ 30,320,791 | \$ 31,843,000 |

The accompanying notes are an integral part of these condensed consolidated

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

financial statements.

4

COMPUTERIZED THERMAL IMAGING, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(UNAUDITED)

| | THREE MONTH PERIOD ENDED SEPTEMBER 30, | |
|--|---|-------------|
| | 2001 | 2000 |
| INCOME: | | |
| Revenues | \$ 207,253 | \$ 79,665 |
| Cost of goods sold | (111,433) | (43,019) |
| GROSS MARGIN | 95,820 | 36,646 |
| OPERATING EXPENSES: | | |
| General and administrative | (2,027,427) | 1,456,417 |
| Research and development | 1,289,413 | 1,789,749 |
| Marketing | 230,237 | 332,164 |
| Depreciation and amortization | 386,567 | 437,787 |
| Litigation settlement | - | - |
| Impairment loss | - | - |
| Total operating expenses (income) | (121,210) | 4,016,117 |
| OPERATING INCOME (LOSS) | 217,030 | (3,979,471) |
| OTHER INCOME (EXPENSE): | | |
| Interest income | 264,724 | 616,842 |
| Interest expense | - | - |
| Other | - | 2,552 |
| Total income | 264,724 | 619,394 |
| INCOME (LOSS) BEFORE EXTRAORDINARY ITEM | 481,754 | (3,360,077) |
| EXTRAORDINARY GAIN ON EXTINGUISHMENT OF DEBT | - | - |
| NET INCOME (LOSS) | 481,754 | (3,360,077) |
| OTHER COMPREHENSIVE INCOME (LOSS) | | |
| Unrealized gain (loss) on investments available for sale | (20,268) | 60,001 |

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

| | | |
|--|------------|----------------|
| TOTAL COMPREHENSIVE INCOME (LOSS) | \$ 461,486 | \$ (3,300,076) |
| | ===== | ===== |
| WEIGHTED AVERAGE SHARES OUTSTANDING | 81,529,282 | 80,405,262 |
| | ===== | ===== |
| BASIC INCOME (LOSS) PER COMMON SHARE | \$ 0.01 | \$ (0.04) |
| | ===== | ===== |
| FULLY DILUTED SHARES OUTSTANDING | 86,569,553 | 80,405,262 |
| | ===== | ===== |
| FULLY DILUTED INCOME (LOSS) PER SHARE | \$ 0.01 | \$ (0.04) |
| | ===== | ===== |

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

COMPUTERIZED THERMAL IMAGING, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

| | COMMON STOCK | | ADDITIONAL | ACCUMULATED |
|-------------------------------|--------------|-----------|--------------------|-------------------------|
| | SHARES | AMOUNT | PAID-IN CAPITAL | COMPREHENSIVE INCOME |
| | ----- | ----- | ----- | ----- |
| Balance at July 1, 2001 | 81,076,546 | \$ 81,077 | \$ 89,910,457 | \$ 106,375 |
| Options exercised for cash | | | | |
| \$0.75 per share | 1,000,000 | 1,000 | 749,000 | |
| \$0.97 per share | 500,000 | 500 | 484,500 | |
| \$1.50 per share | 54,002 | 54 | 132,212 | |
| Stock-based compensation | 50,000 | 50 | (50) | |
| Warrants exercised for cash | | | | |
| \$2.50 per share | 122,715 | 123 | 260,352 | |
| Variable stock options | | | | |
| Compensation marked to market | | | (3,348,669) | |
| Other comprehensive loss | | | | (20,268) |
| Net income | | | | |
| Balance at September 30, 2001 | 82,803,263 | \$ 82,804 | \$ 88,187,802 | \$ 86,107 |
| | ===== | ===== | ===== | ===== |

The accompanying notes are an integral part of these condensed consolidated financial statements

6

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

COMPUTERIZED THERMAL IMAGING, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

| | THREE MONTHS ENDED SEPTEMBER 30, | |
|--|----------------------------------|----------------|
| | 2001 | 2000 |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | |
| Net income (loss) | \$ 481,754 | \$ (3,360,077) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | | |
| Depreciation and amortization | 386,567 | 437,787 |
| Impairment loss | - | - |
| Bond Premium (Discount) Amortization | 48,035 | (23,336) |
| Amortization of debt issuance costs and discounts on notes payable | - | - |
| Common stock, warrants, and options issued as compensation for services | - | - |
| Options extended beyond their expiration date | - | - |
| Common stock issued for interest expense | - | - |
| Stock-based compensation on options marked to market | (3,348,669) | - |
| Common stock issued to settle litigation | - | - |
| Options issued at discount to market to settle litigation | - | - |
| Options issued at discount to market as compensation expense | - | - |
| Common stock issued for failure to complete timely registration | - | - |
| Common stock issued to 401(k) plan | - | - |
| Extraordinary gain on extinguishment of debt | - | - |
| Bad debt expense | 51,925 | 166,894 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable - trade | (230,865) | 122,633 |
| Accounts receivable - other | 384,703 | - |
| Inventories | (303,237) | (250,101) |
| Prepaid expenses | (11,895) | 158,877 |
| Accounts payable | (574,910) | (347,637) |
| Accrued liabilities | (42,066) | - |
| Deferred revenues | 354,200 | - |
| | ----- | ----- |
| Net cash used in operating activities | (2,804,458) | (3,094,960) |
| | ----- | ----- |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Proceeds from sale of assets | - | - |
| Capital expenditures | (100,600) | (469,987) |
| Acquisition of Thermal Imaging, Inc. common stock | - | (40,000) |
| Purchase of software license | - | - |
| Purchase of investments available for sale | (8,160,431) | (1,003,852) |
| Proceeds on redemption of investments available for sale | 8,010,000 | - |
| Acquisition of Bales Scientific common stock, net of cash acquired | - | - |
| | ----- | ----- |

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

| | | |
|---------------------------------------|-----------|-------------|
| Net cash used in investing activities | (251,031) | (1,513,839) |
|---------------------------------------|-----------|-------------|

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

COMPUTERIZED THERMAL IMAGING, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)

| | THREE MONTHS ENDED SEPTEMBER 30, | |
|--|----------------------------------|--------------|
| | 2001 | 2000 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Proceeds from issuance of common stock and warrants, net of offering costs | \$ 1,627,741 | \$ 310,850 |
| Advances to affiliate | - | (22,674) |
| Advances from stockholders | - | - |
| Proceeds from borrowing | - | - |
| Payments on debt | - | - |
| Net cash provided by financing activities | 1,627,741 | 288,176 |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (1,427,748) | 8,860,605 |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR | 7,810,285 | 137,162 |
| CASH AND CASH EQUIVALENTS AT END OF YEAR | \$ 6,382,537 | \$ 8,997,767 |
| SUPPLEMENTAL CASH FLOW INFORMATION | | |
| Cash paid for: | | |
| Interest expense | | |
| Income taxes | | |
| SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES | | |
| Common stock issued to individuals to acquire minority interest of subsidiary | | |
| Common stock issued in consideration of Bales Scientific | | |
| Options issued at discount to market in connection with offering | | |
| Stock offering costs capitalized | | |
| Common stock issued for advances from shareholders | | |
| Common stock issued for notes payable, accrued discount and interest | | |
| Common stock issued for convertible subordinated | | |

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

debentures
Common stock issued for liabilities

The accompanying notes are an integral part of these consolidated financial statements.

8

COMPUTERIZED THERMAL IMAGING, INC.
(A Development Stage Company)
Notes to Condensed Consolidated Financial Statements

NOTE A. UNAUDITED FINANCIAL STATEMENTS AND BASIS OF PRESENTATION

The condensed consolidated financial statements for the three-month periods ended September 30, 2001 and 2000 are unaudited. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation for the periods presented have been included. These interim statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto contained in the Company's most recent Form 10-K. The consolidated results of operations for the three-month periods ended September 30, 2001 and 2000 are not necessarily indicative of the results to be expected for the full year.

Certain amounts from the prior period financial statements have been reclassified to conform with current period presentation.

NOTE B. RECENTLY ISSUED ACCOUNTING STANDARDS

In July 2001, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 141, BUSINESS COMBINATIONS. SFAS 141 requires the purchase method of accounting for business combinations initiated after June 30, 2001 and eliminates the pooling-of-interests method. The Company does not believe that the adoption of SFAS 141 will have a significant impact on its financial statements.

In July 2001, the FASB issued SFAS No. 142, GOODWILL AND OTHER INTANGIBLE ASSETS, which is effective July 1, 2002 for the Company. SFAS 142 requires, among other things, the discontinuance of goodwill amortization. In addition, the standard includes provisions for the reclassification of certain existing intangibles such as goodwill, reassessment of the useful lives of existing recognized intangibles, reclassification of certain intangibles out of previously reported goodwill and the identification of reporting units for purposes of assessing potential future impairments of goodwill. SFAS 142 also requires the Company complete a transitional goodwill impairment test six months from the date of adoption. The Company is currently assessing the impact of SFAS 142 on its financial position and results of operations.

NOTE C. REVENUE RECOGNITION

The Company derives revenue from the sale of industrial and medical equipment, and industrial non-destructive inspection services and design. The Company recognizes revenue only when its customer has assumed the risks and rewards of ownership or upon service completion. The Company records deferred revenue when the sale is subject to a contingency or when payment arrangements differ from its normal domestic or international terms. Deferred revenue is recognized upon expiration of the contingency or collection of the balance due.

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

NOTE D. INVENTORIES

Inventories are stated at the lower-of-cost or market with cost determined using first-in first-out. Inventories consist of the following:

| | September 30, 2001 | June 30, 2001 |
|-----------------------------------|-----------------------|---------------------|
| Raw materials and work-in-process | \$ 625,585 | \$ 341,898 |
| Finished goods | 320,750 | 301,200 |
| | ----- | ----- |
| Total | \$ 946,335 ===== | \$ 643,098 ===== |

NOTE E. INCOME TAXES

The Company accounts for income taxes using the liability method. Under this method, the Company records deferred income taxes to reflect future year tax consequences of temporary differences between the tax basis of assets and liabilities and their financial statement amounts. The Company has reviewed its net deferred tax assets, together with net operating loss carry-forwards, and has provided a valuation allowance to reduce its potential deferred tax assets to their net realizable value.

NOTE F. STOCK WARRANTS, OPTIONS, AND RESTRICTED STOCK

During the three months ended September 30, 2001, the Company issued 122,715 common shares pursuant to the exercise of warrants and 1,554,002 shares pursuant to the exercise of employee stock options. During the quarter, outstanding warrants to purchase 1,939,110 shares of our common stock for \$2.50 per share expired and are no longer exercisable. The Company issued no options or warrants during the three months ended September 30, 2001.

In accordance with Accounting Principles Board Opinion (APB) No. 25 ACCOUNTING FOR STOCK ISSUED TO EMPLOYEES FOR STOCK-BASED COMPENSATION, and Financial Accounting Standards Board Interpretation No. 44, ACCOUNTING FOR CERTAIN TRANSACTIONS INVOLVING STOCK COMPENSATION (AN INTERPRETATION OF APB 25), during the quarter ended September 30, 2001, we recorded a decrease to expenses of \$3,349,000 related to stock-based compensation for 'variable' stock options. This non-cash adjustment represents changes in the difference between the exercise price of certain stock options and the fair market value of the underlying security (the Company's common stock). Because the value of a share of the Company's stock at September 30, 2001 was less than the value of a share at June 30, 2001, we recorded a decrease in previously recognized expense.

NOTE G. CONTINGENCIES

Except as disclosed in our Form 10-K and in Part II, Item 1 of this report, the Company is unaware of any material contingencies.

NOTE H. EARNINGS PER SHARE

Basic and fully diluted earnings per share are based on the net income and the weighted average number of common shares outstanding during each period.

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

For the quarter, ended September 30, 2000, common equivalent shares from common stock options and warrants are excluded from the computation, as their effect would be antidilutive. Options to purchase approximately 916,000 shares of common stock at prices ranging from \$2.95 to \$9.06 per share and warrants to purchase approximately 5,847,000 shares of common stock at prices ranging from \$5.00 to \$7.25 were outstanding during the quarter ended September 30, 2001 but were not included in the computation of diluted EPS because the exercise prices were greater than the average market price of the common shares. Fully diluted earnings per share are as follows:

For the three-month period ended September 30, 2001

| | Income (Numerator) | Shares (Denominator) | Per-Sha Amount |
|-------------------------------------|-----------------------|-------------------------|-------------------|
| Net Income..... | \$ 481,754 ===== | | |
| Basic income per share..... | \$ 481,754 ===== | 81,529,282 | \$.0.01 ===== |
| Effect of dilutive securities | | | |
| Options..... | | 4,411,806 | |
| Warrants..... | | 628,465 ----- | |
| Fully diluted income per share..... | \$ 481,754 ===== | 86,569,553 ===== | \$.0.01 ===== |

For the three-month period ended September 30, 2000

| | Income (Numerator) | Shares (Denominator) | Per-Sha Amount |
|-----------------------------------|-------------------------|-------------------------|-------------------|
| Net Loss..... | \$ (3,300,076) ===== | | |
| Basic loss per share..... | \$ (3,300,076) ===== | 80,405,262 | \$ (0.04 ===== |
| Effect of dilutive securities | | | |
| Options..... | | - | |
| Warrants..... | | - ----- | |
| Fully diluted loss per share..... | \$ (3,300,076) ===== | 80,405,262 ===== | \$ (0.0 ===== |

NOTE I. SEGMENTS

During the current fiscal year, management began to evaluate the Company as two distinct lines of business: medical and industrial products and

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

services. The following table describes operations for each product segment for the three-month periods September 30, 2001 and 2000.

11

Segment results for the three-month period ended September 30, 2001

| | Medical ----- | Industrial ----- | Total ----- |
|-------------------------------|------------------|---------------------|----------------|
| Revenue | \$ 136,680 | \$ 70,573 | \$ 207,253 |
| Gross Margin | 38,830 | 56,990 | 95,820 |
| General & Administrative | (1,642,216) | (385,211) | (2,027,427) |
| Research & Development | 970,066 | 319,347 | 1,289,413 |
| Marketing | 186,492 | 43,745 | 230,237 |
| Depreciation and amortization | 100,529 | 286,038 | 386,567 |
| | ----- | ----- | ----- |
| Operating expense (income) | (385,129) | 263,919 | (121,210) |
| | ----- | ----- | ----- |
| Operating income (loss) | \$ 423,959 | \$ (206,929) | \$ 217,030 |
| | ===== | ===== | ===== |

Segment results for the three-month period ended September 30, 2000

| | Medical ----- | Industrial ----- | Total ----- |
|-------------------------------|------------------|---------------------|----------------|
| Revenue | \$ 76,665 | \$ 3,000 | \$ 79,665 |
| Gross Margin | 33,646 | 3,000 | 36,646 |
| General & Administrative | 1,179,700 | 276,717 | 1,456,417 |
| Research & Development | 1,789,749 | - | 1,789,749 |
| Marketing | 269,053 | 63,111 | 332,164 |
| Depreciation and amortization | 252,636 | 185,151 | 437,787 |
| | ----- | ----- | ----- |
| Operating expense | 3,491,138 | 524,979 | 4,016,117 |
| | ----- | ----- | ----- |
| Operating income (loss) | \$ (3,457,492) | \$ (521,979) | \$ (3,979,471) |
| | ===== | ===== | ===== |

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

This document, and the documents incorporated by reference, contain forward-looking statements within the meaning of the Securities Act of 1933 and Securities Exchange Act of 1934. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied. When used in this document the words "expects", "anticipates," "intends," "plans," "may," "believes," "seeks," "estimates," and similar expressions generally identify forward-looking statements. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and we assume no obligation to update any forward-looking statements.

The following discussion and analysis of our consolidated financial

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

condition and results of operations should be read in conjunction with our Audited Consolidated Financial Statements and Notes thereto contained in our Form 10-K/A for the fiscal year ended June 30, 2001.

12

TRENDS/UNCERTAINTIES AFFECTING CONTINUING OPERATIONS

In January 2001, we began transitioning our focus from research and development to commercializing our technology. Success in this transition depends upon the Company's ability, among other things, to:

- o obtain FDA approval for our Breast Cancer System;
- o develop and manufacture reliable and effective products;
- o attract, retain, train and motivate qualified personnel;
- o develop manufacturing and marketing expertise and expand our internal sales force; and
- o attract qualified distributors.

We have had limited revenues from operations. To date, the Company has generated revenues from the Photonic Stimulator, TIP, Turbine Blade Inspection System and inspection services. We cannot assure you that we will achieve profitability in the near future.

GENERAL

Computerized Thermal Imaging, Inc. ("we", "us", "our", "CTI", "the Company") designs, manufactures and markets thermal imaging devices and services used for clinical diagnosis, pain management and industrial non-destructive testing. The Company markets its products worldwide through an internal sales force and a network of independent distributors.

From its inception in 1987, the Company has emphasized the research and development of thermal imaging equipment and proprietary imaging technology. These efforts have led to the development of our non-invasive and non-destructive infrared imaging systems. We believe our thermal imaging system generates data, difficult to obtain or not available using other imaging modalities, that are useful to health care providers in the detection of certain diseases and disorders and useful to industry as a tool for product quality testing.

Our research indicates that our equipment and technology is useful in studying and diagnosing breast cancer, which is the most common cancer in women after skin cancers. Our research and development efforts have led to the creation of our Breast Cancer System 2100(TM) ("Breast Cancer System"). We are seeking FDA pre-market approval ("PMA") for this system, as an adjunct to mammography and clinical examinations, for use as a painless and non-invasive technique for acquiring clinical information. To receive FDA approval, we must establish the Breast Cancer System's ability to consistently distinguish between malignant and benign tissue and thereby significantly reduce the number of unnecessary (benign finding) breast biopsies performed. We have received acceptance on four of five modules required for PMA approval. We submitted the fifth module, which includes clinical trial results and efficacy claims, during June 2001. We are awaiting FDA review and comment.

13

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

In addition to breast cancer screening, we believe our technologies may have application in pain treatment and non-destructive testing of industrial and structural components. We design, manufacture and sell our Thermal Image Processor ("TIP") and Photonic Stimulator for pain treatment. We have developed industrial applications for our technology that address industrial markets for non-destructive testing and inspection of turbine blades, aging aircraft, electronics, composites, metals and other advanced materials.

As of September 30, 2001, the Company had approximately 82.8 million shares of common stock held by approximately 29,000 shareholders, primarily individuals. We have warrants and options for approximately 14.7 million shares of common stock that remain unexercised. Accordingly, on a fully diluted basis, we have approximately 97.6 million common shares outstanding. In addition, we own 100 percent of Bales Scientific, Inc. We have no other interest in any other entity. We trade on the American Stock Exchange under the symbol "CIO".

The Company uses capital to pay general corporate expenses, including salaries, manufacturing costs, professional fees, clinical trials and technical support costs, and general and administrative expenses. To date, the Company has funded its business activities with funds raised through the private placement of its common stock and warrants and the exercise of warrants and options.

RESULTS OF OPERATIONS

Quarter Ended September 30, 2001 Compared to Quarter Ended September 30, 2000.

REVENUES

Revenues for the quarter ended September 30, 2001, increased \$128,000 from the same period last year to \$207,000, of which approximately \$137,000 resulted from the sale of pain management products and the \$70,000 from the sale of industrial products and services. During the quarter ended September 30, 2000 all of the Company's \$80,000 in revenues resulted from the sale of pain management products.

During the quarter ended September 30, 2001, medical segment revenues increased \$57,000, or 71%, from the same period last year to \$137,000. During the quarter ended September 30, 2000, medical segment revenues were \$80,000.

During the quarter ended September 30, 2001, the Company's new industrial segment recorded revenues of \$70,000 through its Bales Scientific, Inc. subsidiary. During the quarter ended September 30, 2000, the Company had no industrial segment revenues.

14

COSTS AND EXPENSES

General and administrative expenses for the quarter ended September 30, 2001, were (\$2,027,000) compared to \$1,456,000 for the same period last year. Excluding a non-cash compensation benefit of \$2,789,000, general and administrative expenses for the quarter ended September 30, 2001 decreased \$694,000, or 47.7%, from the same quarter in 2000 to \$761,000. This decrease is primarily a result of 1) a \$439,000 decrease in legal fees; 2) a \$167,000 decrease in professional services expense; and 3) a \$216,000 decrease in stockholder service costs. These expense reductions were partially offset by a \$70,000 increase in wage expense.

Research and development expenses for the quarter ended September 30,

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

2001, were \$1,289,000 compared to \$1,790,000 for the same period last year. Excluding a non-cash compensation benefit of \$202,000, research and development expenses for the quarter ended September 30, 2001, decreased \$299,000, or 17%, from the same quarter in 2000, to \$1,491,000. The decrease is primarily a result of 1) a \$166,000 decrease in clinical trial expenses; 2) a \$435,000 decrease in consulting services associated with the development of our breast imaging system; 3) \$164,000 decrease in software license fees. This reduction in expenses was partially offset by 1) a \$313,000 increase in salaries as a result of an increase in the number of research and development employees; 2) a \$91,000 increase in office expenses; and 3) a \$74,000 increase in supplies and equipment expense.

Marketing expenses for the quarter ended September 30, 2001, were \$230,000 compared to \$332,000 for the same period last year. Excluding a non-cash compensation benefit of \$358,000, marketing expenses for the quarter ended September 30, 2001, increased \$256,000, or 77.3%, from the same quarter in 2000 to \$589,000. The increase was mainly attributable to \$171,000 increase in wages and benefits and a \$78,000 increase in office expenses and travel. These increased expenses are associated with developing a marketing team in connection with our transition into an operating company.

Depreciation and amortization expense for the quarter ended September 30, 2001, decreased \$51,000, or 11.7% from the same quarter in 2000 to \$387,000. The decrease in depreciation and amortization expense resulted from asset impairments and write offs recorded in the fourth quarter of our 2000 fiscal year.

During the three months ended September 30, 2001, we decreased our monthly average expense level \$246,000, or 20%, to \$946,000 from \$1,192,000 during the same quarter last year.

NET INTEREST INCOME

Interest income for the quarter ended September 30, 2001 decreased \$352,000, or 57% from the same quarter of 2000 to \$265,000. This decrease results from lower interest rates and decreased cash balances available for investment.

NET INCOME/(LOSS)

As a result of the foregoing, we recorded net income of \$482,000 for the quarter ended September 30, 2001, compared to a loss of \$3,360,000 for the quarter ended September 30, 2000.

15

For the quarter ended September 30, 2001, the profit attributable to common shareholders was \$482,000, or \$0.01 per share, compared to a loss attributable to common shareholders of \$3,360,000, or \$(0.04) per share, for the quarter ended September 30, 2000.

LIQUIDITY AND CAPITAL RESOURCES

SOURCES OF LIQUIDITY

Our net working capital at September 30, 2001, was \$17.1 million compared to \$18.7 million at June 30, 2001. The ratio of current assets to current liabilities was 8.1 to 1.0 at September 30, 2001, compared to 7.8 to 1.0 at June 30, 2001.

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

Our cash requirements consist of, but are not limited to, general corporate expenses including office salaries and expenses, lease payments on our office space, acquisition of technology, legal and accounting fees to comply with securities registration and reporting requirements, costs of clinical trials and technical support, and FDA consulting expenses.

Net cash used in operating activities for the quarter ended September 30, 2001 was \$2,804,000 compared to \$3,095,000 for the quarter ended September 30, 2000, an improvement of \$291,000 or 9.4%. Net cash used by investing activities in the 2001 period was \$ 251,000 compared to net cash used in investing activities of \$1,514,000 in the prior year's comparable period, an improvement of \$1,263,000 or 83.4%. Net cash provided by financing activities was \$1,627,000 in the quarter ended September 30, 2001 compared to \$288,000 during the same quarter last year, an improvement of \$1,339,000 or 464.9%.

As a result of the foregoing, cash and cash equivalents decreased by \$1,428,000 in the quarter ended September 30, 2001, compared to a \$4,321,000 decrease in the quarter ended September 30, 2000, an improvement of \$2,893,000 or 67.0%.

Capital resources needed to meet our planned expenditures are derived primarily from equity funding on the private placement of our common stock and warrants and the exercise of our outstanding warrants and options.

Agreement with Beach Boulevard, LLC -----

On March 4, 1999, we entered into a Securities Purchase Agreement (as amended in May 1999, the "Investment Agreement") with Beach Boulevard L.L.C. ("Beach"). Subject to certain conditions set forth in the Investment Agreement, we have the right to require Beach to purchase up to \$7 million of our common stock in a series of \$500,000 tranches. As of the date hereof, we have required Beach to purchase approximately \$3 million of our common stock in a series of six tranches during our fiscal years ended June 30, 2000 and 1999. Since Beach's participation in the sixth tranche, we have made no requirements of funding by Beach, although Beach's obligation to provide funding, subject to the terms and conditions set forth in the Investment Agreement, continues.

16

Because Beach is not required to purchase additional shares unless certain conditions are satisfied as set forth in the Investment Agreement, there is no assurance that Beach will ultimately provide us with the remaining \$4 million commitment. Furthermore, there is no assurance that we will require Beach to purchase additional shares even if the conditions set forth in the Investment Agreement are satisfied.

CAPITAL REQUIREMENTS/PLAN OF OPERATION

Since inception, we have generated significant losses from operations. Although our recently acquired subsidiary, Bales Scientific, has generated limited revenues during the past several years, it is also a development stage enterprise. Our cash requirements consist of, but are not limited to: general corporate expenses including salaries and benefits, lease payments for office space, technology acquisition, legal and accounting fees, clinical trial and technical support, FDA consulting, marketing, and expenses associated with the private placement of our equity securities. Capital resources needed to meet our past and planned expenditures have been financed and are likely to continue to be primarily from the sale of equity securities. As of September 30, 2001, we had approximately \$17.1 million in working capital.

Our capital requirements may vary from our estimates and depend upon

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

numerous factors including, but not limited to: a) progress in our research and development programs; b) results of pre-clinical and clinical testing; c) costs of technology; d) time and costs involved in obtaining regulatory approvals; e) costs of filing, defending and enforcing any patent claims and other intellectual property rights; f) the economic impact of competing technological and market developments; and g) the terms of any new collaborative, licensing and other arrangements that we may establish.

We believe we will have sufficient capital to fund our business plan over the next year. If additional capital is required, we will rely on private investors to support us either through loans or contributions to capital in exchange for restricted common stock.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a development stage enterprise. We believe we are not subject to market risks beyond ordinary economic risks, such as interest rate fluctuation and inflation.

At September 30, 2001, we had invested approximately \$11.2 million in available-for-sale marketable securities including investments in United States government securities and corporate bonds and \$5.5 million in cash available to invest in available-for-sale marketable securities. Although we believe the issuers of these marketable securities are solvent and are favorably rated by recognized rating agencies, there is the risk that such issuers may not have sufficient liquid assets to satisfy their obligations at the time such obligations become due. If such were to occur, we may not be able to recover the full amount of our investment.

Each of our marketable securities has a fixed rate of interest. Accordingly, a change in market interest rates may result in an increase or decrease in the market value of our marketable securities. If we liquidate any of our marketable securities prior to the time of their maturity, we could receive less than the face value of the security.

17

PART II-- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

KATHLEEN SULLIVAN EMPLOYMENT AGREEMENT

On June 27, 2000, Kathleen Sullivan ("Plaintiff") filed a complaint in the Superior Court of California for the County of Los Angeles (Central District), alleging breach of contract for failure to compensate her for promotional services rendered to the Company. In March 2001, Plaintiff amended her complaint to include causes of action for fraud and negligent misrepresentation against us and a former officer. Plaintiff seeks unspecified damages. We believe Ms. Sullivan breached the agreement and intend to defend this lawsuit on that basis. No trial date has been set.

ALEX SAENZ COMPLAINT AND COUNTERCLAIMS

On June 1, 2000, we filed a complaint against Alex Saenz ("defendant") in the Circuit Court of the State of Oregon. On July 7, 2000, the complaint was moved from the circuit court to the United States District Court for the District of Oregon.

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

We believe that defendant interfered with our business by threatening lawsuits to recover stock options allegedly owed to him in connection with our April 2000 Private Placement, and threatening to sue and otherwise harass an individual important to the continued conduct of our business. The defendant has denied our allegations and filed a counterclaim alleging breach of various verbal agreements to compensate him for services rendered.

Following a trial that ended August 16, 2001, the court ruled that defendant was not entitled to any additional compensation from our company. The court also dismissed the defendant's counterclaim against the company. The defendant has appealed to the 9th Circuit Court of Appeals where the matter will be briefed.

BLOOMBERG/EVANS DEFAMATION ACTION

On August 28, 2000, we filed a complaint for libel in the United States District Court for the District of Utah against Bloomberg, L.P. ("Bloomberg"). The lawsuit alleges that on June 29 and July 18, 2000, Bloomberg published certain defamatory articles about the Company through its news service. We allege damages in excess of One Hundred Million Dollars (\$100,000,000).

On March 26, 2001, the Court dismissed our complaint against Bloomberg, without prejudice. The Court ruled that, despite the possibility that a jury could have found Bloomberg's statements defamatory, damages had not been sufficiently pleaded. We had alleged that Bloomberg's statements directly caused a decline in our stock price and that the price decline did not merely "coincide" with those statements, as Bloomberg maintained. The court held that any decline in our stock value attributable to Bloomberg's statements may be damage to our shareholders, but not necessarily to the Company itself .

We have appealed the District Judge's decision to the Federal 10th Circuit Court of Appeals in Denver, Colorado, where the matter will be briefed soon.

18

SALAH AL-HASAWI ADVISORY SERVICES CLAIM

On March 29, 2000, Salah Al-Hasawi ("Plaintiff"), a citizen and resident of Kuwait, filed an action in the United States District Court for the Southern District of New York, against us and our former Chief Executive Officer, alleging violations under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, for commissions allegedly due to Plaintiff in connection with the private placement of our securities. Shortly thereafter, the Plaintiffs lawsuit was dismissed without prejudice and on April 12, 2000, the Plaintiff filed a similar complaint in the United States District Court for the District of Utah. Plaintiff seeks specified damages, attorney fees and unspecified damages pursuant to five separate causes of action including breach of contract, fraud and unjust enrichment.

We have denied all of Plaintiffs claims and have affirmatively alleged that all amounts due have been paid in full. We are currently engaged in discovery and the no trial date has yet been set.

DAVID PACKER VS. COMPUTERIZED THERMAL IMAGING. INC.

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

On March 19, 2001, we entered into a Separation Agreement with David A. Packer. Under that agreement, Packer's employment with the Company was to terminate on December 31, 2001.

On June 13, 2001, the Company communicated its intent to terminate the agreement based upon information discovered subsequent to the signing of that agreement regarding alleged misrepresentations made by Packer in regard to his employment duties. The Company also cancelled 1,000,000 options granted to Mr. Packer under the agreement.

Packer filed suit against the Company in Davis County, Utah on June 19, 2001 in an attempt to recover the benefits and compensation, including the 1,000,000 options, that were contemplated under the agreement. The Company has filed a counterclaim against Packer for breach of contract, misrepresentation, and a declaration that the Separation Agreement is void. We are currently engaged in discovery and the no trial date has yet been set.

19

ITEM 2. CHANGES IN SECURITIES

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5. OTHER INFORMATION

FDA Approval Status

Our Breast Cancer System qualifies as a medical device because of its intended use in the diagnosis of disease while not interacting chemically with the body. We have chosen to pursue FDA PMA approval, the most stringent type of device marketing application required by FDA, because we believe that PMA approval will enhance our ability to introduce our system to the market by: 1) allowing us to reference medical efficacy claims in connection with marketing our Breast Cancer System, 2) improving physician acceptance of our systems, and 3) obtaining designation of insurance payment codes.

We submitted our Pre-Market Application in 5 modules. We submitted the fifth and final module, an evaluation of our clinical studies during June 2001. While we cannot determine when or whether the FDA will approve our Pre-Market Application, the FDA is performing the in-depth scientific, regulatory and manufacturing reviews and inquiries required by its procedures. In connection with its reviews, the FDA has requested additional data and discussion to help them complete their evaluation. The data requested has been furnished and we anticipate further information requests and discussions. The same procedures were performed in connection with securing FDA approvals for Modules 1 through 4. After the FDA staff completes its work, the PMA will be subjected to an advisory panel for review and recommendation. After the FDA receives the advisory panel recommendation, it will complete its documentation and issue a decision.

20

Edgar Filing: COMPUTERIZED THERMAL IMAGING INC - Form 10-Q

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

COMPUTERIZED THERMAL IMAGING, INC.
(Registrant)

Dated November 9, 2001 /s/Richard V. Secord

Richard V. Secord
Chairman & Chief Executive Officer

Dated November 9, 2001 /s/Bernard J. Brady

Bernard J. Brady
Chief Financial Officer, Secretary & Treasurer